Target intelligence / Profile preview

Natural killer group 2D ligands (NKG2DL)

Target
NKG2DL
Molecular classification
Other
01

Overview

Natural killer group 2D ligands (NKG2DLs), including MHC class I polypeptide-related sequence A and B (MICA/MICB) and UL16-binding proteins 1 to 3 (ULBP1-3), are stress-induced cell-surface glycoproteins. Under normal physiological conditions, these ligands are minimally expressed or absent on healthy tissues. However, they become significantly upregulated on the surface of cells undergoing cellular stress, viral infection, or malignant transformation. When expressed on tumor cells, they engage the activating immunoreceptor NKG2D on natural killer (NK) cells, CD8+ T cells, and gamma-delta T cells, triggering cytotoxic immune responses and cytokine production to eliminate the abnormal cells.

To evade this immune surveillance, tumor cells frequently employ sheddases (such as ADAM10 and ADAM17 metalloproteinases) to proteolytically cleave MICA/MICB and ULBPs from their cell surface. This shedding process releases soluble ligands (sNKG2DLs) into the circulation, which act as decoys, downregulate NKG2D receptor expression on effector cells, and suppress anti-tumor immunity. Therapeutic strategies targeting these stress ligands include monoclonal antibodies (e.g., CLN-619) that bind to MICA/MICB to prevent their proteolytic shedding and promote antibody-dependent cellular cytotoxicity (ADCC). Additionally, chimeric antigen receptor (CAR) T-cell and NK-cell therapies (such as CYAD-01, CYAD-02, and NKX101) utilize the extracellular domain of NKG2D to target and eliminate tumor cells expressing these stress ligands.

Other names
NKG2D ligandsNKG2DLsMICA/MICB and ULBP1-3MHC class I polypeptide-related sequence A/B and UL16-binding proteins 1-3Stress-induced ligandsTumor stress ligands
02

Mechanism of action

Inhibition of MICA/MICB proteolytic shedding, promotion of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and chimeric antigen receptor (CAR) T-cell or NK-cell activation leading to tumor cell lysis.

03

Biological functions

Immune responseSignal transductionCell deathApoptosis
04

Disease associations

CancerInfectionInflammation
05

Safety considerations

Cytokine release syndrome (CRS)On-target, off-tumor toxicityGraft-versus-host disease (GvHD)Immune evasion via ligand sheddingFratricide of CAR-T cells
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

MICA/MICB cell surface expressionSoluble MICA/MICB (sMICA/sMICB) serum levelsULBP1/2/3 cell surface expressionSoluble ULBP1/2/3 (sULBP1/2/3) serum levelsNKG2D receptor expression on NK cells and CD8+ T cells

Beyond the preview

Go deeper on Natural killer group 2D ligands (NKG2DL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural killer group 2D ligands (NKG2DL).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call